^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Medulloblastoma
    Drug:buparlisib (AN2025) (PI3K inhibitor) +
    Farydak (panobinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    1330 - Novel dual inhibitors of HDAC and PI3Kinase signaling pathways in treatment of p53 driven medulloblastoma

    Published date:
    03/10/2021
    Excerpt:
    p53-mutant MB cell line was used to investigate the signaling pathway that regulates proliferation, migration, and drug resistance using inhibitors of HDAC (LBH-589) and PI3K/mTOR [Buparlisib (BKM-120)/rapamycin)]or CUDC-907 (dual inhibitor of HDACs and PI3K/AKT). Results demonstrated that...Combined treatment with LBH-589 and BKM-120 or single treatment with CUDC-907 inhibited cell proliferation, migration and S-phase entry...